Long-term efficacy of infliximab maintenance therapy for perianal Crohn’s disease

Table 1 Patients' characteristics n (%)

	Surgery + infliximab (n = 26)	Surgery alone (n = 36)	P value
Male:Female	16:10	27:9	0.26
Age at initial surgery (median years and range)	27.5 (16-55)	27.5 (16-41)	0.73
Duration from onset of perianal lesion (median month and range)	45 (2.5-275.5)	120 (26.5-339.5)	< 0.01
Duration from initial surgery for perianal lesion	28.2 (0.57-62.4)	74.5 (7.4-218.9)	< 0.01
(median month and range)
Types of fistula
Intrasphincteric	7 (26.9)	4 (11.1)	0.11
Transsphincteric	12 (46.2)	16 (44.4)	0.89
Suprasphincteric	4 (15.4)	8 (22.2)	0.5
Extrasphincteric	3 (11.5)	8 (22.2)	0.28
Anorectal stricture	19 (73.1)	21 (58.3)	0.23
Current smoking	8 (30.8)	16 (44.4)	0.28

Data are numbers with percentage in parentheses unless otherwise indicated.

Table 2 Present status of surgical treatment

	IFX (-)	IFX (+)	P value
APR	9/36	3/26	0.19
Duration from initial surgery to APR, median yr (range)	2.5 (0-4.3)	3.9 (1.0-4.1)	0.79
Hartmann's procedure	10/36	4/26	0.25
Duration from initial surgery to Hartmann, median yr (range)	2.3 (0-7.0)	0.7 (0-2.9)	0.22

APR: Abdominoperineal resection; IFX : Infliximab.